Short-course remdesivir for healthcare-associated COVID-19: Case series from a non-acute care hospital.
Short-course remdesivir for healthcare-associated COVID-19: Case series from a non-acute care hospital.
复制标题
DOI：
10.1016/j.jiac.2022.08.025
复制
发表时间：
2023-01
影响因子：
2.2
通讯作者：
Doi, Yohei
中科院分区：
文献类型：
--
作者：
Takahashi, Yu;Wakita, Hideaki;Ishihara, Takuma;Okazaki, Hideto;Ito, Akihiro;Iwata, Mitsunaga;Sonoda, Shigeru;Doi, Yohei
弱势患者中与医疗保健相关的 COVID-19 导致发病率和死亡率不成比例。早期药物干预可能会减少不良后遗症并提高此类情况下的生存率。本研究旨在描述接受早期短期瑞德西韦治疗的医疗相关 COVID-19 患者的结果。我们回顾了在日本一家非急症护理医院的两个病房爆发期间感染 COVID-19 并接受短期瑞德西韦治疗的住院患者的特征和结果。 49 名患者被诊断出患有 COVID-19，其中 34 名患者在综合住院康复病房，15 名患者在姑息治疗和内科综合病房。 47 人出现症状，其中 46 人接受了瑞德西韦治疗。接受治疗的患者中位年龄为 75 岁，查尔森合并症指数中位为 6。 41 名患者接受了一剂或两剂 mRNA 疫苗，但没有人接受过第三剂。大多数患者接受了 3 天的瑞德西韦治疗。在发病后 14 天和 28 天随访的患者中，分别有 41/44 (95.3%) 和 35/41 (85.4%) 存活。截至 28 天，姑息治疗/内科病房发生 6 例死亡，其中两人可能与 COVID-19 有关。在幸存者中，从发病时到 28 天，体能状态没有变化。
Healthcare-associated COVID-19 among vulnerable patients leads to disproportionate morbidity and mortality. Early pharmacologic intervention may reduce negative sequelae and improve survival in such settings. This study aimed to describe outcome of patients with healthcare-associated COVID-19 who received early short-course remdesivir therapy. We reviewed the characteristics and outcome of hospitalized patients who developed COVID-19 during an outbreak that involved two wards at a non-acute care hospital in Japan and received short-course remdesivir. Forty-nine patients were diagnosed with COVID-19, 34 on a comprehensive inpatient rehabilitation ward and 15 on a combined palliative care and internal medicine ward. Forty-seven were symptomatic and 46 of them received remdesivir. The median age was 75, and the median Charlson comorbidity index was 6 among those who received it. Forty-one patients had received one or two doses of mRNA vaccines, while none had received a third dose. Most patients received 3 days of remdesivir. Of the patients followed up to 14 and 28 days from onset, 41/44 (95.3%) and 35/41(85.4%) were alive, respectively. Six deaths occurred by 28 days in the palliative care/internal medicine ward and two of them were possibly related to COVID-19. Among those who survived, the performance status was unchanged between the time of onset and at 28 days.
登录
查看更多内容
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
DOI：
10.1056/nejmoa2116846
发表时间：
2022-01-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
Gottlieb RL;Vaca CE;Paredes R;Mera J;Webb BJ;Perez G;Oguchi G;Ryan P;Nielsen BU;Brown M;Hidalgo A;Sachdeva Y;Mittal S;Osiyemi O;Skarbinski J;Juneja K;Hyland RH;Osinusi A;Chen S;Camus G;Abdelghany M;Davies S;Behenna-Renton N;Duff F;Marty FM;Katz MJ;Ginde AA;Brown SM;Schiffer JT;Hill JA;GS-US-540-9012 (PINETREE) Investigators
通讯作者：
GS-US-540-9012 (PINETREE) Investigators
DOI：
10.1016/j.cmi.2022.02.040
发表时间：
2022-06
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Prendki V;Tiseo G;Falcone M;ESCMID Study Group for Infections in the Elderly (ESGIE)
通讯作者：
ESCMID Study Group for Infections in the Elderly (ESGIE)
DOI：
10.1056/nejmoa2118542
发表时间：
2022-04-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hammond J;Leister-Tebbe H;Gardner A;Abreu P;Bao W;Wisemandle W;Baniecki M;Hendrick VM;Damle B;Simón-Campos A;Pypstra R;Rusnak JM;EPIC-HR Investigators
通讯作者：
EPIC-HR Investigators
影响因子：
158.5
作者：
Gupta, Anil;Gonzalez-Rojas, Yaneicy;Shapiro, Adrienne E.
通讯作者：
Shapiro, Adrienne E.